Funders › AZ › Ben and Catherine Ivy Foundation › 2022
Grants paid by Ben and Catherine Ivy Foundation, tax year 2022
EIN 27-3322123 · Scottsdale, AZ · Form 990-PF, Part XV · NTEE T20
In tax year 2022, Ben and Catherine Ivy Foundation (EIN 27-3322123) reported 24 grants paid totaling $15,341,725. Dataset version 2026.09.0, built 2026-09-03.
Every grant, 2022
| Tax year | Recipient | Match | Amount | Type | Purpose | Source filing |
|---|---|---|---|---|---|---|
| 2022 | Neurotrials LLC Phoenix, AZ | U | $5,470,000 | paid | PREPAYMENT OF 2023 CEREBROSPINAL FLUID ANALYSIS. | 202312089349100511 |
| 2022 | Neuro Trials LLC Phoenix, AZ | U | $5,000,000 | paid | IVY BRAIN TUMOR CENTER BUILDING EXPANSION SPECIAL GRANT AMENDMENT. | 202312089349100511 |
| 2022 | Neurotrials LLC Phoenix, AZ | U | $450,000 | paid | CEREBROSPINAL FLUID ANALYSIS WITH T-GEN. | 202312089349100511 |
| 2022 | Mayo Clinic College of Medicine Rochester, MN | U | $300,000 | paid | EVALUATE CANDIDATE GLIOMA CSF PROTEOMIC SIGNATURES TO HELP UNDERSTAND AND MONITOR GLIOMA EVOLUTION IN LIVING PATIENTS DURING STANDARD OF CARE AND EXPERIMENTAL IMMUNOTHERAPY. PAYMENT 1 OF 2. | 202312089349100511 |
| 2022 | Univ of New Mexico Health Sciences Albuquerque, NM | D | $300,000 | paid | IDENTIFY MECHANISMS UNDERLYING INFLAMMATORY CELL CONTRIBUTION TO THE EMERGENCE OF THE RECURRENT TUMOR BY SINGLE-CELL ANALYSIS OF RESIDUAL DISEASE IN GLIOBLASTOMA PATIENTS. PAYMENT 2 OF 2. | 202312089349100511 |
| 2022 | University of Michigan Ann Arbor, MI | U | $300,000 | paid | NEW METHODS WILL BE DEVELOPED TO MEASURE THE ACTIVITY OF TUMOR METABOLIC PATHWAYS IN PATIENTS WITH GLIOBLASTOMA AND TO DETERMINE WHETHER DRUGS DESIGNED TO BLOCK THESE PATHWAYS ARE SUITABLE. PAYMENT 2 OF 2. | 202312089349100511 |
| 2022 | University of Tx Md Anderson Cancer Houston, TX | U | $300,000 | paid | PROJECT SEEKS TO PRECLINICALLY OPTIMIZE NOVEL THERAPEUTIC APPROACHES FOR ATRX-DEFICIENT MALIGNANT GLIOMAS TARGETING G-QUADRUPLEX DNA SECONDARY STRUCTURE. PAYMENT 1 OF 2. | 202312089349100511 |
| 2022 | Swedish Medical Center Seattle, WA | C | $300,000 | paid | ASSESS COMBINATIONS OF SMALL MOLECULES AND IMMUNOTHERAPIES FOR KILLING GLIOBLASTOMA TUMOR CELLS IN A PERSONALIZED EX VIVO ECOSYSTEM WITH INTACT TUMOR MICROENVIRONMENT USING MULTIPLEX IMMUNOCHEMISTRY AND SPATIAL MAPPING OF CELL TYPES. PAYMENT 1 OF 2. | 202312089349100511 |
| 2022 | Univ of Miami Miller School of Medi Miami, FL | U | $300,000 | paid | USING PATIENT DERIVED ORTHOTOPIC XENOGRAFT MODELS AND A NOVEL IMMUNOCOMPETENT MODEL OF GBM, THE EFFICACY OF A MTl-MMP INHIBITOR IN COMBINATION WITH RADIATION/TMZ WILL BE TESTED TO DETERMINE ITS EFFECTS ON THE IMMUNE COMPONENT OF THE TUMOR MICROENVIRONMENT. PAYMENT 2 OF 2. | 202312089349100511 |
| 2022 | H Lee Moffitt Cancer Center Rochester, MN | U | $300,000 | paid | IN EXAMINING THE ROLE OF TUMORS CELLS IN MODULATING BONE MARROW-DERIVED MACROPHAGES AND MICROGLIA, THIS STUDY SEEKS TO TAILOR NOVEL THERAPEUTICS FOR TARGETING OF TUMOR ASSOCIATED MACROPHAGES. PAYMENT 2 OF 2. | 202312089349100511 |
| 2022 | Yale Cancer Center New Haven, CT | U | $300,000 | paid | USE OF A NOVEL TRANSFORMATIONAL PLATFORM FOR RAPID IDENTIFICATION OF TARGETS AND TREATMENTS TO INHIBIT GROWTH AND INVASION OF GLIOBLASTOMA CELLS BASED ON RAPID PATIENT SAMPLE SCREENING USING NOVEL NANO-ENGINEERING TECHNIQUES. PAYMENT 2 OF 2. | 202312089349100511 |
| 2022 | Mayo Clinic Jacksonville, FL | U | $268,998 | paid | IDENTIFY THE ONCOGENIC SIGNALING DEPENDENCIES THAT CHARACTERIZE EACH OF THE CELLULAR SUBPOPULATIONS THAT COMPRISE A GLIOBLASTOMA TUMOR, AND FROM THIS INFORMATION CONSTRUCT A NON-TOXIC COMBINATION OF KINASE INHIBITORS TO EFFECTIVELY TREAT THIS DISEASE. PAYMENT 1 OF 2. | 202312089349100511 |
| 2022 | University of Tx Md Anderson Cancer Houston, TX | U | $250,000 | paid | DEVELOP SAFE AND POTENT DRUGS THAT CAN TURN THE TUMOR IMMUNE MICROENVIRONMENT FROM SUPPRESSIVE TO PERMISSIVE, THEREBY HELPING THE IMMUNE SYSTEM TO RECOGNIZE AND KILL GLIOBLASTOMA. PAYMENT 1 OF 2. | 202312089349100511 |
| 2022 | Society of St Vincent de Paul Phoenix, AZ | C | $250,000 | paid | CENTER FOR FAMILY WELLNESS ESTABLISHED TO FOCUS ON THE PREVENTION AND MANAGEMENT OF CHRONIC DISEASES THROUGH NUTRITION, PHYSICAL ACTIVITY AND OVERALL WELLNESS. ITS CULTURALLY GROUNDED BILINGUAL EDUCATION PROGRAMS ENCOURAGE THE WHOLE FAMILY TO PARTICIPATE. PAYMENT #3. | 202312089349100511 |
| 2022 | Vanderbilt University Nashville, TN | C | $250,000 | paid | USING SINGLE-CELL AND SYSTEMS BIOLOGY APPROACHES IN GLIOBLASTOMA, CELL SUBTYPES WILL BE MAPPED TO GLIOBLASTOMA TISSUES AND EXPERIMENTAL MODELS, ENABLING IDENTIFICATION AND PRECLINICAL TARGETING OF INTERACTIONS BETWEEN CANCER CELLS, IMMUNE CELLS, AND LOCATION SPECIFIC RESIDENT BRAIN CELLS. PAYMENT 2 OF 2. | 202312089349100511 |
| 2022 | Columbia University Irving Medical New York, NY | U | $250,000 | paid | TARGETING THE GLIOBLASTOMA MASTER REGULATOR CEBP A PHARMACOKINETICS AND PHARMACODYNAMICS SURGICAL STUDY OF ST101. PAYMENT 1 OF 2. | 202312089349100511 |
| 2022 | Ut Southwestern Medical Center Dallas, TX | U | $210,430 | paid | PRECLINICAL INVESTIGATION OF FOCUS ULTRASOUND GUIDED DELIVERY TO FACILITATE A LIPOPROTEIN-OMEGA-3 FATTY ACID-BASED BIOLOGICAL THERAPY IN GLIOBLASTOMA. PAYMENT 2 OF 2. | 202312089349100511 |
| 2022 | Mayo Clinic College of Medicine Rochester, MN | U | $208,347 | paid | IMMUNOSTIMULATORY BACTERIAL ANTIGENS EXPRESSED IN ONCOLYTIC VIRAL PLATFORMS WILL BE TESTED IN PRECLINICAL MODELS OF GLIOBLASTOMA TO OVERCOME IMMUNE CHECKPOINT INHIBITOR RESISTANCE. PAYMENT 2 OF 2. | 202312089349100511 |
| 2022 | Neuro Trials LLC Phoenix, AZ | U | $200,000 | paid | DEPOSIT FOR IVY BRAIN TUMOR CENTER BUILDING LOBBY. | 202312089349100511 |
| 2022 | Damon Runyon Cancer Research Fdn New York, NY | U | $120,000 | paid | INVESTIGATION OF A BIOMARKER PHASE 2 STUDY TO EVALUATE TARGETED THERAPY HARBORING SPECIFIC GENETIC ALTERATIONS. PAYMENT 3 | 202312089349100511 |
| 2022 | Arcs Foundation Artesia, CA | U | $8,800 | paid | ADVANCE SCIENCE AND TECHNOLOGY IN THE UNITED STATES BY PROVIDING AWARDS TO ACADEMICALLY OUTSTANDING US CITIZENS STUDYING TO COMPLETE DEGREES IN SCIENCE, ENGINEERING AND MEDICAL RESEARCH. | 202312089349100511 |
| 2022 | Barrow Neurological Fdn Phoenix, AZ | B | $4,500 | paid | PROVIDES PHILANTHROPIC SUPPORT FOR BARROW NEUROLOGICAL INSTITUTE AT ST. JOSEPH'S HOSPITAL AND MEDICAL CENTER. BARROW IS AN INTERNATIONAL LEADER IN THE TREATMENT, RESEARCH, AND EDUCATION OF BRAIN AND SPINAL DISEASES, CONDITIONS AND INJURIES. | 202312089349100511 |
| 2022 | O'connor Institute Phoenix, AZ | U | $500 | paid | ADVANCES SANDRA DAY O'CONNOR'S DISTINGUISHED LEGACY AND LIFETIME WORK TO ADVANCE CIVICS EDUCATION, CIVIC ENGAGEMENT AND CIVIL DISCOURSE. | 202312089349100511 |
| 2022 | Lung Cancer Research Foundation New York, NY | U | $150 | paid | IMPROVES LUNG CANCER OUTCOMES BY FUNDING RESEARCH FOR THE PREVENTION, DIAGNOSIS, TREATMENT AND CURE OF LUNG CANCER. | 202312089349100511 |
Match tier: A Reported EIN · B Exact name and place · C Strong name match · D Probable name match · U Unresolved. Tiers C and D are inferred, not reported; see how matching works.
Recipient matching for this dataset version has not yet completed its independent precision check. Tier A rows carry the EIN the filer reported; tiers B–D are the matcher's inference and should be read as leads until the check is published on the methodology page.
Derived from IRS Form 990-PF e-file XML. Dataset version 2026.09.0, built 2026-09-03. All years for this funder.
The same organization elsewhere in the program: exempt status and filing health · federal awards · grant guidance · open opportunities.
This is informational only, derived from public data on the dates shown. It is not an eligibility determination, and not legal, tax, or accounting advice. Verify against the official source before relying on it.